查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1855057

類器官和球狀體的全球市場:各類型，各來源，各用途，各終端用戶，各地區-市場規模，產業動態，機會分析，預測(2025年～2033年)

Global Organoids And Spheroids Market: By Type, Source, Application, End-User, Region- Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 433 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

受對更精確的疾病和組織三維模型的需求不斷增長的推動，類器官和球狀體市場正經歷顯著增長。因此，到 2024 年，市場規模已達到約 10.7258 億美元，反映出這些技術的強勁應用和投資。展望未來，預計該市場將快速擴張，到 2033 年的估值將達到 66.1397 億美元。這一增長意味著 2025 年至 2033 年預測期內的複合年增長率 (CAGR) 為 22.4%。多種因素正在推動這一強勁成長。

監管機構越來越支持在研究和測試中使用非動物模型，這使得類器官和球狀體作為一種符合倫理且有效的替代方案更具吸引力。此外，製藥業的巨額投資正在加速這些模型的開發和應用，因為各公司都在尋求更具預測性和效率的藥物測試和開發方法。

市場動態

類器官和球狀體市場競爭激烈，眾多參與者共同造就了充滿活力的市場環境。像賽默飛世爾科技（Thermo Fisher Scientific）和默克集團（Merck KGaA）這樣的老牌公司憑藉其雄厚的資源和豐富的產品線，擁有巨大的市場影響力。除了這些行業領導者之外，像STEMCELL Technologies和InSphero AG這樣的專業公司專注於細分領域，為類器官和球狀體領域提供針對性的解決方案，並推廣特定的應用。

為了鞏固其市場地位，默克集團於2024年12月收購了HUB Organoids。此次收購為默克的產品組合新增了70種經過驗證的類器官模型，並增強了其為科研提供多樣化、可靠的生物模型的能力。憑藉這一發展勢頭，默克公司於2025年5月與IMEC合作，共同開發一個能夠同時分析1000個類器官的尖端平台。此次合作旨在顯著提高類器官研究的通量和效率，並體現了該領域向高通量、可擴展技術發展的持續趨勢。

成長驅動因素

類器官和球狀體市場正迅速從傳統的生物醫學研究擴展到化妝品和化學品安全測試等新的應用領域。這一轉變在很大程度上是由日益嚴格的法規推動的，這些法規旨在減少或消除動物試驗——動物試驗曾是評估產品安全性的標準方法。為了應對這些監管壓力，企業正擴大採用先進的3D類器官模型——尤其是皮膚和眼部類器官——這些模型為毒性和安全性評估提供了更符合倫理、更準確、更貼近人體的替代方案。歐萊雅2024年的願景就是這一趨勢的一個典型例證，該願景旨在將皮膚類器官的年產量提升至驚人的10萬個。這些類器官被廣泛用於毒理學篩選，以評估化妝品成分和配方的安全性和有效性。

新興商業機會趨勢

在類器官智慧（也稱為生物運算）這個新興領域，隨著研究人員利用腦類器官的運算能力，突破性的、面向未來的商業機會正在湧現。這種創新方法探索了利用活體神經組織作為生物處理器的潛力，有望徹底改變我們對運算和人工智慧的認知。 2024年，約翰霍普金斯大學的一個計畫取得了顯著進展，獲得了50萬美元的初始資金，用於開發由1萬個相互連接的腦類器官組成的生物電腦。這項投資凸顯了人們對基於類器官的計算系統執行複雜資訊處理任務的潛力的日益增長的信心。

優化障礙

類器官球體市場面臨的一大挑戰是這些3D模型缺乏血管，這大大限制了它們在長期功能研究中的應用。血管生成，即血管的形成，對於活體組織中營養物質、氧氣的輸送和代謝廢物的清除至關重要。如果沒有這種複雜的血管網絡，類器官和球體就難以長期維持其活性和功能，這限制了它們模擬完全發育器官生理條件的能力。這種限制阻礙了研究人員進行長期實驗的能力，而這些實驗對於理解慢性疾病、藥物代謝和長期治療效果至關重要。

目錄

第1章 調查架構

  • 調查目的
  • 產品概要
  • 市場區隔

第2章 調查手法

  • 定性調查
    • 一級資訊來源·二級資訊來源
  • 定量調查
    • 一級資訊來源·二級資訊來源
  • 初步調查受訪者的明細:各地區
  • 調查的前提
  • 市場規模·估計
  • 資料三角測量

第3章 摘要整理:類器官和球狀體的全球市場

第4章 全球類器官和球狀體市場概要

  • 產業價值鏈分析
    • 廠商
    • 供應商
    • 終端用戶
  • 產業的展望
  • 大環境分析
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商業者的威脅
    • 競爭的程度
  • 市場動態和趨勢
    • 成長促進因素
    • 阻礙因素
    • 課題
    • 主要趨勢
  • COVID-19對市場成長趨勢的影響評估
  • 市場成長與展望
    • 市場收益估計·預測，2020年～2033年
    • 價格趨勢分析
  • 競爭儀表板
    • 市場集中率
    • 企業佔有率分析(金額%)、2024年
    • 競爭製圖

第5章 類器官和球狀體的全球市場分析:各類型

  • 主要洞察
  • 市場規模·預測，2020年～2033年
    • 類器官
    • 球狀體

第6章 類器官和球狀體的全球市場分析:各方法

  • 主要洞察
  • 市場規模·預測，2020年～2033年
    • 類器官
    • 球狀體

第7章 類器官和球狀體的全球市場分析:各來源

  • 主要洞察
  • 市場規模·預測，2020年～2033年
    • 類器官
    • 球狀體

第8章 類器官和球狀體的全球市場分析:各用途

  • 主要洞察
  • 市場規模·預測，2020年～2033年
    • 發生生物學
    • 個人化醫療
    • 再生醫療
    • 疾病病理學研究
    • 醫藥品的毒性·有效性實驗

第9章 類器官和球狀體的全球市場分析:各終端用戶

  • 主要洞察
  • 市場規模·預測，2020年～2033年
    • 生物科技·製藥產業
    • 學術·研究機關
    • 醫院·診斷中心

第10章 類器官和球狀體的全球市場分析:各地區

  • 主要洞察
  • 市場規模·預測，2020年～2033年
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第11章 北美的類器官和球狀體市場分析

第12章 歐洲的類器官和球狀體市場分析

第13章 亞太地區的類器官和球狀體市場分析

第14章 中東·非洲的類器官和球狀體市場分析

第15章 南美的類器官和球狀體市場分析

第16章 美國的類器官和球狀體市場分析

第17章 加拿大的類器官和球狀體市場分析

第18章 墨西哥的類器官和球狀體市場分析

第19章 英國的類器官和球狀體市場分析

第20章 德國的類器官和球狀體市場分析

第21章 法國的類器官和球狀體市場分析

第22章 義大利的類器官和球狀體市場分析

第23章 西班牙的類器官和球狀體市場分析

第24章 波蘭的類器官和球狀體市場分析

第25章 俄羅斯的類器官和球狀體市場分析

第26章 其他歐洲的類器官和球狀體市場分析

第27章 日本的類器官和球狀體市場分析

第28章 企業簡介

  • 3D BioMatrix
  • 3D Biotek LLC
  • AMS Biotechnology(Europe)Limited
  • ATCC
  • Cellesce Ltd
  • Corning Incorporated
  • Greiner Bio-One
  • Hubrecht Organoid Technology(HUB)
  • InSphero/Perkin Elmer
  • Kuraray
  • Lonza
  • Merck KGaA
  • Prellis Biologics
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific, Inc.
  • 其他的主要企業
簡介目錄
Product Code: AA0423422

The organoids and spheroids market is experiencing significant growth driven by the increasing demand for more accurate three-dimensional models of diseases and tissues. As a result, the market size reached approximately US$ 1,072.58 million in 2024, reflecting strong adoption and investment in these technologies. Looking ahead, the market is projected to expand rapidly, with an estimated valuation of US$ 6,613.97 million by 2033. This growth translates to a compound annual growth rate (CAGR) of 22.4% over the forecast period from 2025 to 2033. Several factors are driving this robust expansion.

Regulatory agencies are increasingly supporting the use of non-animal models for research and testing, which elevates the appeal of organoids and spheroids as ethical and effective alternatives. Additionally, substantial investments from the pharmaceutical industry are accelerating the development and application of these models, as companies seek more predictive and efficient methods for drug testing and development.

Noteworthy Market Developments

The organoids and spheroids market is characterized by intense competition, with a diverse range of players contributing to its dynamic landscape. Large, well-established corporations such as Thermo Fisher Scientific and Merck KGaA hold significant influence due to their extensive resources and broad product offerings. Alongside these industry giants, specialized companies like STEMCELL Technologies and InSphero AG focus on niche areas, providing targeted solutions and advancing specific applications within the organoid and spheroid space.

In a strategic move to strengthen its position, Merck KGaA acquired HUB Organoids in December 2024. This acquisition expanded Merck's portfolio by adding 70 validated organoid models, enhancing its capabilities in providing diverse and reliable biological models for research. Building on this momentum, Merck entered into a partnership with IMEC in May 2025 to develop a cutting-edge platform designed to analyze 1,000 organoids simultaneously. This collaboration aims to significantly increase throughput and efficiency in organoid research, reflecting the ongoing trend toward high-capacity, scalable technologies in the field.

Core Growth Drivers

The organoids and spheroids market is rapidly expanding beyond traditional biomedical research into new application areas such as cosmeceuticals and chemical safety testing. This shift is largely driven by increasingly stringent regulations aimed at reducing or eliminating animal testing, which has historically been the standard method for evaluating product safety. In response to these regulatory pressures, companies are increasingly adopting advanced 3D organoid models, particularly skin and eye organoids, that offer more ethical, accurate, and human-relevant alternatives for toxicity and safety assessments. A prime example of this trend is seen in L'Oreal's 2024 initiative to scale up the production of skin organoids to an impressive 100,000 units annually. These organoids are utilized extensively in toxicology screening to evaluate the safety and efficacy of cosmetic ingredients and formulations.

Emerging Opportunity Trends

A groundbreaking and futuristic opportunity is unfolding in the emerging field of Organoid Intelligence, also known as biocomputing, where researchers are leveraging the computational capabilities of brain organoids. This innovative approach explores the possibility of using living neural tissue as biological processors, potentially revolutionizing the way we think about computation and artificial intelligence. In 2024, a notable milestone was reached when a project at Johns Hopkins University secured an initial funding of US$ 500,000 to develop a biocomputer composed of 10,000 interconnected brain organoids. This investment underscores growing confidence in the potential of organoid-based computing systems to perform complex information processing tasks.

Barriers to Optimization

One of the critical challenges facing the organoids and spheroids market is the lack of vascularization within these 3D models, which significantly limits their use in long-term functional studies. Vascularization-the formation of blood vessel networks-is essential for supplying nutrients, oxygen, and removing waste products in living tissues. Without this complex vascular network, organoids and spheroids struggle to maintain viability and functionality over extended periods, which restricts their ability to mimic the physiological conditions of fully developed organs. This limitation hampers researchers' capacity to conduct prolonged experiments that are crucial for understanding chronic diseases, drug metabolism, and long-term therapeutic effects.

Detailed Market Segmentation

By Type, the organoids segment is solidifying its dominant position within the organoids and spheroids market, with projections indicating that it will account for over 53% of the total revenue share. This prominent leadership is largely attributed to organoids' advanced capacity to mimic the intricate structure and diverse functionality of human organs more accurately than other models. Unlike simpler two-dimensional cultures or even spheroids, organoids recreate the complex cellular architecture and microenvironment found in actual human tissues, making them highly valuable for a wide range of biomedical applications.

By Application, the developmental biology segment is poised to dominate the organoids and spheroids market, expected to capture a substantial 32.1% share of the overall market. This leadership position is largely attributed to the unique and unparalleled insights that these three-dimensional (3D) models provide into fundamental biological processes. Organoids and spheroids have revolutionized the study of complex phenomena such as organogenesis, embryogenesis, and tissue development by allowing researchers to observe and analyze these intricate events in a controlled and human-relevant environment.

By End Users, the pharmaceutical and biotechnology industry stands as the foremost end-user segment in the organoids and spheroids market, expected to capture more than 47.4% of the total revenue share. This dominant position is driven by the urgent demand within these industries for more predictive and human-relevant preclinical models during drug development and testing. Traditional animal models have long been the standard for evaluating drug safety and efficacy, but their limitations have become increasingly apparent. Approximately 90% of drugs fail to receive approval from regulatory bodies like the FDA, despite promising results in animal studies. This high failure rate highlights a significant efficiency gap in the drug development pipeline, causing delays, increased costs, and lost opportunities.

Segment Breakdown

By Type

  • Organoids
  • Neural Organoids
  • Hepatic Organoids
  • Intestinal Organoids
  • Kidney Organoids
  • Other Organoids
  • Spheroids
  • Multicellular tumor spheroids (MCTS)
  • Neurospheres
  • Mammospheres
  • Hepatospheres
  • Embryoid bodies

By Method

  • Organoids
  • General Submerged Method for Organoid Culture
  • Crypt Organoid Culture Techniques
  • Air Liquid Interface (ALI) Method for Organoid Culture
  • Clonal Organoids from Lgr5+ Cells
  • Brain and Retina Organoid Formation Protocol
  • Spheroids
  • Micropatterned Plates
  • Low Cell Attachment Plates
  • Hanging Drop Method
  • Others

By Source

  • Organoids
  • Primary Tissues
  • Stem Cells
  • Spheroids
  • Cell Line
  • Primary Cell
  • iPSCs Derived Cell

By Application

  • Developmental Biology
  • Personalized Medicine
  • Regenerative Medicine
  • Disease Pathology Studies
  • Drug Toxicity & Efficacy Testing

By End User

  • Biotechnology and pharmaceutical industries
  • Academic & Research Institutes
  • Hospitals and diagnostic centers

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a leading position in the organoids and spheroids market, commanding over 40.60% of the global market share. This dominance is underpinned by strong financial support and the presence of advanced research infrastructure across the region. The United States, in particular, has made significant strides in advancing organoid technology through substantial funding initiatives and regulatory advancements. In 2024, the U.S. National Cancer Institute (NCI) invested in 45 new research projects dedicated specifically to developing patient-derived cancer organoids, signaling a focused commitment to leveraging this technology for cancer research and personalized medicine.
  • Regulatory progress has also been a key factor contributing to North America's leadership. The U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) launched a pilot program in 2024 aimed at qualifying five different organ-on-a-chip platforms for regulatory submissions. This initiative reflects growing recognition of organoid and microphysiological systems as valuable tools in drug development and safety assessment. Such regulatory support not only facilitates innovation but also helps streamline the pathway for organoid-based technologies to enter clinical and commercial applications.

Leading Market Participants

  • 3D BioMatrix
  • 3D Biotek LLC
  • AMS Biotechnology (Europe) Limited
  • ATCC
  • Cellesce Ltd
  • Corning Incorporated
  • Greiner Bio-One
  • Hubrecht Organoid Technology (HUB)
  • InSphero/Perkin Elmer
  • Kuraray
  • Lonza
  • Merck KGaA
  • Prellis Biologics
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific, Inc.
  • Other Prominent Players.

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Organoids and Spheroids Market

Chapter 4. Global Organoids and Spheroids Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Manufacturers
    • 4.1.2. Providers
    • 4.1.3. End User
  • 4.2. Industry Outlook
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Challenges
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2033
    • 4.7.2. Price Trend Analysis
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2024
    • 4.8.3. Competitor Mapping

Chapter 5. Global Organoids and Spheroids Market Analysis, By Type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 5.2.1. Organoids
      • 5.2.1.1. Neural Organoids
      • 5.2.1.2. Hepatic Organoids
      • 5.2.1.3. Intestinal Organoids
      • 5.2.1.4. Kidney Organoids
      • 5.2.1.5. Other Organoids
    • 5.2.2. Spheroids
      • 5.2.2.1. Multicellular tumor spheroids (MCTS)
      • 5.2.2.2. Neurospheres
      • 5.2.2.3. Mammospheres
      • 5.2.2.4. Hepatospheres
      • 5.2.2.5. Embryoid bodies

Chapter 6. Global Organoids and Spheroids Market Analysis, By Method

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 6.2.1. Organoids
      • 6.2.1.1. General Submerged Method for Organoid Culture
      • 6.2.1.2. Crypt Organoid Culture Techniques
      • 6.2.1.3. Air Liquid Interface (ALI) Method for Organoid Culture
      • 6.2.1.4. Clonal Organoids from Lgr5+ Cells
      • 6.2.1.5. Brain and Retina Organoid Formation Protocol
    • 6.2.2. Spheroids
        • 6.2.2.1.1. Micropatterned Plates
        • 6.2.2.1.2. Low Cell Attachment Plates
        • 6.2.2.1.3. Hanging Drop Method
        • 6.2.2.1.4. Others

Chapter 7. Global Organoids and Spheroids Market Analysis, By Source

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 7.2.1. Organoids
      • 7.2.1.1. Primary Tissues
      • 7.2.1.2. Stem Cells
    • 7.2.2. Spheroids
      • 7.2.2.1. Cell Line
      • 7.2.2.2. Primary Cell
      • 7.2.2.3. iPSCs Derived Cell

Chapter 8. Global Organoids and Spheroids Market Analysis, By Application

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 8.2.1. Developmental Biology
    • 8.2.2. Personalized Medicine
    • 8.2.3. Regenerative Medicine
    • 8.2.4. Disease Pathology Studies
    • 8.2.5. Drug Toxicity & Efficacy Testing

Chapter 9. Global Organoids and Spheroids Market Analysis, By End User

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 9.2.1. Biotechnology and pharmaceutical industries
    • 9.2.2. Academic & Research Institutes
    • 9.2.3. Hospitals and diagnostic centers

Chapter 10. Global Organoids and Spheroids Market Analysis, By Region

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 10.2.1. North America
      • 10.2.1.1. The U.S.
      • 10.2.1.2. Canada
      • 10.2.1.3. Mexico
    • 10.2.2. Europe
      • 10.2.2.1. Western Europe
        • 10.2.2.1.1. The UK
        • 10.2.2.1.2. Germany
        • 10.2.2.1.3. France
        • 10.2.2.1.4. Italy
        • 10.2.2.1.5. Spain
        • 10.2.2.1.6. Rest of Western Europe
      • 10.2.2.2. Eastern Europe
        • 10.2.2.2.1. Poland
        • 10.2.2.2.2. Russia
        • 10.2.2.2.3. Rest of Eastern Europe
    • 10.2.3. Asia Pacific
      • 10.2.3.1. China
      • 10.2.3.2. India
      • 10.2.3.3. Japan
      • 10.2.3.4. South Korea
      • 10.2.3.5. Australia & New Zealand
      • 10.2.3.6. ASEAN
      • 10.2.3.7. Rest of Asia Pacific
    • 10.2.4. Middle East & Africa
      • 10.2.4.1. UAE
      • 10.2.4.2. Saudi Arabia
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of MEA
    • 10.2.5. South America
      • 10.2.5.1. Argentina
      • 10.2.5.2. Brazil
      • 10.2.5.3. Rest of South America

Chapter 11. North America Organoids and Spheroids Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 11.2.1. By Type
    • 11.2.2. By Method
    • 11.2.3. By Source
    • 11.2.4. By Application
    • 11.2.5. By End Use
    • 11.2.6. By Country

Chapter 12. Europe Organoids and Spheroids Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 12.2.1. By Type
    • 12.2.2. By Method
    • 12.2.3. By Source
    • 12.2.4. By Application
    • 12.2.5. By End Use
    • 12.2.6. By Country

Chapter 13. Asia Pacific Organoids and Spheroids Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 13.2.1. By Type
    • 13.2.2. By Method
    • 13.2.3. By Source
    • 13.2.4. By Application
    • 13.2.5. By End Use
    • 13.2.6. By Country

Chapter 14. Middle East & Africa Organoids and Spheroids Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 14.2.1. By Type
    • 14.2.2. By Method
    • 14.2.3. By Source
    • 14.2.4. By Application
    • 14.2.5. By End Use
    • 14.2.6. By Country

Chapter 15. South America Organoids and Spheroids Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 15.2.1. By Type
    • 15.2.2. By Method
    • 15.2.3. By Source
    • 15.2.4. By Application
    • 15.2.5. By End Use
    • 15.2.6. By Country

Chapter 16. The US Organoids and Spheroids Market Analysis

  • 16.1. Key Insights
  • 16.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 16.2.1. By Type
    • 16.2.2. By Method
    • 16.2.3. By Source
    • 16.2.4. By Application
    • 16.2.5. By End Use

Chapter 17. Canada Organoids and Spheroids Market Analysis

  • 17.1. Key Insights
  • 17.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 17.2.1. By Type
    • 17.2.2. By Method
    • 17.2.3. By Source
    • 17.2.4. By Application
    • 17.2.5. By End Use

Chapter 18. Mexico Organoids and Spheroids Market Analysis

  • 18.1. Key Insights
  • 18.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 18.2.1. By Type
    • 18.2.2. By Method
    • 18.2.3. By Source
    • 18.2.4. By Application
    • 18.2.5. By End Use

Chapter 19. The UK Organoids and Spheroids Market Analysis

  • 19.1. Key Insights
  • 19.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 19.2.1. By Type
    • 19.2.2. By Method
    • 19.2.3. By Source
    • 19.2.4. By Application
    • 19.2.5. By End Use

Chapter 20. Germany Organoids and Spheroids Market Analysis

  • 20.1. Key Insights
  • 20.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 20.2.1. By Type
    • 20.2.2. By Method
    • 20.2.3. By Source
    • 20.2.4. By Application
    • 20.2.5. By End Use

Chapter 21. France Organoids and Spheroids Market Analysis

  • 21.1. Key Insights
  • 21.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 21.2.1. By Type
    • 21.2.2. By Method
    • 21.2.3. By Source
    • 21.2.4. By Application
    • 21.2.5. By End Use

Chapter 22. Italy Organoids and Spheroids Market Analysis

  • 22.1. Key Insights
  • 22.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 22.2.1. By Type
    • 22.2.2. By Method
    • 22.2.3. By Source
    • 22.2.4. By Application
    • 22.2.5. By End Use

Chapter 23. Spain Organoids and Spheroids Market Analysis

  • 23.1. Key Insights
  • 23.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 23.2.1. By Type
    • 23.2.2. By Method
    • 23.2.3. By Source
    • 23.2.4. By Application
    • 23.2.5. By End Use

Chapter 24. Poland Organoids and Spheroids Market Analysis

  • 24.1. Key Insights
  • 24.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 24.2.1. By Type
    • 24.2.2. By Method
    • 24.2.3. By Source
    • 24.2.4. By Application
    • 24.2.5. By End Use

Chapter 25. Russia Organoids and Spheroids Market Analysis

  • 25.1. Key Insights
  • 25.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 25.2.1. By Type
    • 25.2.2. By Method
    • 25.2.3. By Source
    • 25.2.4. By Application
    • 25.2.5. By End Use

Chapter 26. Rest of Europe Organoids and Spheroids Market Analysis

  • 26.1. Key Insights
  • 26.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 26.2.1. By Type
    • 26.2.2. By Method
    • 26.2.3. By Source
    • 26.2.4. By Application
    • 26.2.5. By End Use

Chapter 27. Japan Organoids and Spheroids Market Analysis

  • 27.1. Key Insights
  • 27.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 27.2.1. By Type
    • 27.2.2. By Method
    • 27.2.3. By Source
    • 27.2.4. By Application
    • 27.2.5. By End Use

Chapter 28. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 28.1. 3D BioMatrix
  • 28.2. 3D Biotek LLC
  • 28.3. AMS Biotechnology (Europe) Limited
  • 28.4. ATCC
  • 28.5. Cellesce Ltd
  • 28.6. Corning Incorporated
  • 28.7. Greiner Bio-One
  • 28.8. Hubrecht Organoid Technology (HUB)
  • 28.9. InSphero/Perkin Elmer
  • 28.10. Kuraray
  • 28.11. Lonza
  • 28.12. Merck KGaA
  • 28.13. Prellis Biologics
  • 28.14. STEMCELL Technologies Inc.
  • 28.15. Thermo Fisher Scientific, Inc.
  • 28.16. Other Prominent Players.